{"id":"NCT03002077","sponsor":"Naurex, Inc, an affiliate of Allergan plc","briefTitle":"Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder","officialTitle":"An Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-03","primaryCompletion":"2018-12-06","completion":"2018-12-06","firstPosted":"2016-12-23","resultsPosted":"2020-06-22","lastUpdate":"2020-06-22"},"enrollment":617,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"Rapastinel","otherNames":[]}],"arms":[{"label":"Rapastinel","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the long-term safety and tolerability of rapastinel as an adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD).","primaryOutcome":{"measure":"The Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"52 Weeks","effectByArm":[{"arm":"Rapastinel","deltaMin":457,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":128,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.allerganclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":617},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Headache","Dysgeusia","Nausea"]}}